Delivery Order SPE2DX15D9237-SPE2DX24F72CM
Award Date
8/21/24
Potential Completion Date
9/12/24
Potential Value
$8.6K
Federal Agency
Medical Supply Chain
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA) under the Medical Supply Chain program. The firm fixed-price delivery order, valued at $7,146.90, has an ultimate completion date of September 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications, including branded and generic...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $8,576.28 for the supply of NEXPLANON 68 MG IMPLANTS. The award was made by the Defense Logistics Agency (DLA) under the SPE2DB program, which is an indefinite delivery contract (IDC) with a ceiling value of up to $499,999,999 that runs through December 31, 2025. DMS Pharmaceutical Group holds this single-award IDC to provide a comprehensive range of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, provides for the delivery of NEXPLANON 68 MG IMPLANTS to the Department of Defense (DoD) and Department of Veterans Affairs (VA) medical facilities. The firm fixed-price delivery order, valued at $4,288.14, was awarded on September 25, 2024, with an ultimate completion date of October 17, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) for the delivery of NEXPLANON 68 MG IMPLANTS. The $8,576.28 firm fixed-price delivery order falls under a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA to supply a comprehensive range of pharmaceutical items to military health facilities worldwide. There is no set-aside designation for...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order valued at $8,576.28. The contract is for the supply of NEXPLANON 68 MG IMPLANTS to the Department of Defense's Medical Supply Chain. The award does not have a set-aside designation. This contract is issued under a larger Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group Inc. holds with the Defense Logistics Agency (DLA) under the SPE2DB program. The...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $5,717.52 for the supply of NEXPLANON 68 MG IMPLANTS. The award was made by the Defense Logistics Agency (DLA), a defense agency, under the SPE2DB program, which is an indefinite delivery contract (IDC) valued at up to $499,999,999. The IDC allows the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to support the recurring medical...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the supply of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The award has a ceiling value of $7,146.90 and is a firm fixed-price delivery order contract with an ultimate completion date of August 28, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical supplies to support the recurring...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The $30,200.64 firm fixed-price delivery order was awarded on May 4, 2022, with a completion date of May 25, 2022. DMS Pharmaceutical Group is a key supplier of pharmaceutical products and medical supplies to the Department of Defense (DoD) healthcare system under a $499,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of NEXPLANON 68 MG IMPLANTS, with a ceiling value of $7,146.90 and a period of performance through September 27, 2024. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed-price delivery order worth $3,573.45 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of NEXPLANON 68 MG IMPLANTS. This order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with the DLA, valued up to $4,999,999 through 2025, which enables the agency to order a broad range of pharmaceutical products to support military health...